Articles tagged "HLA antibodies"

2020 American Transplant Congress
CD56^DimCD16^Bright NK Cells from Kidney Transplant Recipients with Antibody-Mediated Rejection Display Increased Proliferation, Self-Renewal, Pro-Inflammatory and Cytotoxic Profile
E. A. Bailly¹, K. Louis¹, C. Macedo¹, B. Ramaswami¹, M. Lucas¹, A. Zeevi¹, C. Lefaucheur², D. Metes¹
¹Department of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ²INSERM UMR-S976. Endothelium, Inflammation & Alloreactivity, Université de Paris, France
*Purpose: Contribution of NK cells to antibody-mediated rejection (ABMR) injuries have recently been highlighted through transcriptomic analysis and immunohistochemistry of kidney and heart allograft biopsies.…
2020 American Transplant Congress
Single Dose Rituximab and Anti-Thymocyte Globulin (ATG) Induction in Hypersensitized Kidney Transplant Recipients
A. X. Wang, U. Wang, S. Busque, C. R. Lenihan
Stanford University School of Medicine, Stanford, CA
*Purpose: Hypersensitized kidney transplant recipients (calculated panel reactive antibody (cPRA) ≥98%) may represent a population at high risk of posttransplant immunologic events. While access to…
2020 American Transplant Congress
Follow Up of Imlifidase (IdeS) Desensitized Kidney Transplant Recipients
S. C. Jordan¹, R. A. Montgomery², T. Lundgren³, C. Legendre⁴, N. Desai⁵, G. Eckerwall⁶, L. Laxmyr⁶, H. Olsson⁶, A. Runström⁶, Å. Schiött⁶, K. Sjöholm⁶, E. Sonesson⁶, L. Winstedt⁶, T. Lorant⁷, C. Kjellman⁶
¹Cedars Sinai Medical Center, Los Angeles, CA, ²NYU Langone Health Transplant Institute, New York, NY, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Hospital Necker & Paris Descartes University, Paris, France, ⁵Johns Hopkins University, Baltimore, MD, ⁶Hansa Biopharma AB, Lund, Sweden, ⁷Uppsala University, Uppsala, Sweden
*Purpose: 46 highly sensitized patients received kidney transplants after desensitization with imlifidase (currently under investigation) across four Phase 2 clinical trials, and 6-month safety and…
2020 American Transplant Congress
Development and Impact of DSA after Lung Transplant
M. Henderson¹, G. Morris², C. Burt¹, A. Feist¹, J. Kozuch¹, E. Schonhoft³, G. Yung³, T. Floreth³, K. Afshar³, E. Golts⁴, M. Mariski¹
¹Pharmacy, University of California San Diego Health, San Diego, CA, ²Immunology, University of California San Diego Health, San Diego, CA, ³Pulmonology, University of California San Diego Health, San Diego, CA, ⁴Cardiothoracic Surgery, University of California San Diego Health, San Diego, CA
*Purpose: Antibody-mediated rejection (AMR) after lung transplant (LT) is a serious complication, potentially leading to graft failure despite advances in drug therapy. Diagnosis and treatment…
2020 American Transplant Congress
The Liver Protects All? Donor Specific Antibody Formation in Heart-Liver Transplant Recipients
A. W. Rogers¹, T. N. Eagar², C. Pham¹, J. Krisl¹, B. J. Pierce¹, M. Moaddab¹, R. Ghobrial³, B. Trachtenberg⁴, A. Bhimaraj⁴, A. O. Gaber³
¹Department of Pharmacy, Houston Methodist Hospital, Houston, TX, ²Department of Pathology, Houston Methodist Hospital, Houston, TX, ³Department of Surgery, Houston Methodist Hospital, Houston, TX, ⁴Houston Methodist Hospital, Houston, TX
*Purpose: Donor specific antibodies (DSAs) are key in the development of antibody mediated rejection (AMR). Their role in decreased patient and graft survival has been…
2020 American Transplant Congress
Epitope Analysis of Complement-Binding De Novo Donor-Specific HLA Class II Antibody
K. Yamanaka, M. Hashimoto, T. Kinoshita, Y. Fujita, S. Matsumura, T. Imanaka, A. Taniguchi, T. Yoshida, H. Kishikawa
Department of Kidney Transplantation Center, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan
*Purpose: Patients with de novo donor specific antibody (dnDSA) after kidney transplantation have a poorer prognosis than patients without dnDSA. Meanwhile, patients with dnDSA do…
2020 American Transplant Congress
Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation
J. P. Knorr, C. Kallis, D. A. Portley, A. Jeyarajasingam, P. W. Lai, G. Bradauskaite, K. Khanmoradi
Transplant Nephrology, Einstein Medical Center, Philadelphia, PA
*Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and…
2020 American Transplant Congress
De Novo DSA in the Setting of Stable Renal Allograft Function Does Not Impair Long-Term Graft Survival
R. Knight¹, D. T. Nguyen², E. A. Graviss², O. Gaber¹
¹Surgery, Houston Methodist Hospital, Houston, TX, ²Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX
*Purpose: To determine the long-term outcome of renal allograft recipients with de novo DSA (dnDSA) in the setting of stable allograft function.*Methods: A single-center review…
2020 American Transplant Congress
The Impact of Epitope Mismatch Load and Shared Targeting Epitopes between De Novo Donor Specific Antibody (DSA) and Non-DSA Third Party HLA Antibody on Lung Transplantation Outcomes
A. Zhang¹, D. Good¹, D. Thomas¹, J. Allen¹, K. McCurry², M. Budev²
¹Allogen Laboratories, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
*Purpose: Rapid advancements in HLA typing and antibody identification technologies allow for enhanced HLA compatibility assessment at the epitope level to aid in the reduction…
2020 American Transplant Congress
Are HLA-DQ De Novo Donor-Specific Antibodies a Risk Factor for Acute Humoral Rejection?
R. Hod Dvorai¹, C. A. Hubbell¹, M. R. Laftavi², R. Shahbazov², B. Gallay³, O. G. Pankewycz³
¹Pathology, SUNY Upstate Medical University, Syracuse, NY, ²Surgery, SUNY Upstate Medical University, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY
*Purpose: To identify HLA-DQ de novo donor-specific antibodies (dnDSA) characteristics associated with acute humoral rejection (ABMR) and response to treatment.*Methods: We performed a retrospective analysis…